Over the past few days, you may have heard about the issue regarding reimbursement of blue light cystoscopy. As all of you know, there are very few treatments and innovations for bladder cancer. It is BCAN’s position that everyone should have equal access to all treatments, tests and innovations that have been approved by the FDA.
When reimbursement is restricted, it limits access for patients to care that may improve their quality of life. As a patient advocacy organization, this is an important issue to us and the bladder cancer community.
This is the key issue as outlined by Photocure:
The Centers for Medicare & Medicaid Services (CMS), the government agency that runs the Medicare program, has adopted a new policy for reimbursing hospitals for the drug Cysview®, which is a breakthrough drug used in the first line treatment of Non-Muscle Invasive Bladder Cancer. Cysview®, used with a Blue Light Cystoscope, is an important advancement in over 30 years, allowing Urologists to identify and remove cancerous lesions from the bladder. Studies have shown that using Blue Light Cystoscopy with Cysview® allows Urologists to make better management decisions and also help reduce the probability of recurrence of non-muscle invasive bladder cancer. CMS’s new policy, however, will not reimburse hospitals for the costs of Cysview®.
You can have your voice heard by contacting members of Congress and Senators to reverse the CMS decision to “package” payment of Cysview® into the procedure payment classification, and provide adequate reimbursement.
To get involved, go to http://www.savebladdercancertreatment.com to write to your representatives directly. The website will allow you to search for your respective Congress member and send a letter to them.